



SUVEN Life Sciences

Communication to investors
Sep 2012

14-Nov-12

2012-13 Q2 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW

Quarter 2 – Sep 2012



• Growth in revenue	4.61%
• Growth in PAT	153.35%
• Growth in EBIDTA	174.43%
• Growth in Pre-R&D EBIDTA	39.47%
• Increase in R&D costs	-22.17%
• R&D cost on revenue	13.59%

FINANCIAL QUICK VIEW

Half year – Sep 2012




MAJOR PROFITABILITY RATIOS



	Q2 Sep 12	HY Sep 12
PAT to Income	12.91%	11.97%
EBIDTA to Income	21.88%	20.58%
Cash Flow to Income	16.29%	14.89%
Pre-R&D EBITDA to Income	35.47%	33.48%



INCOME COMPARISON




14-Nov-12

2012-13 Q2 results




PROFIT COMPARISON






EBIDTA COMPARISON



14-Nov-12

2012-13 Q2 results


R & D – EXPENDITURE



14-Nov-12

2012-13 Q2 results

PRE-R&D EBIDTA




14-Nov-12

2012-13 Q2 results



PRE-R&D CASHFLOW



14-Nov-12

2012-13 Q2 results



Updates for the quarter

- During the quarter the major qualitative achievement include Suven getting Pharmexcil's "Platinum Patent Award" for securing the most number of product and process patents under overall category, fourth year in a row.
- Suven has a patent profile of 18 inventions, 541 product patents and 36 process patents.
- The product profile has 13 molecules with one molecule having completed phase 1 study, is in the process of moving into phase 2a, proof of concept study.